NeoGenomics Stock Price Drops 7.9%

Analysts Weigh In on Whether Investors Should Sell

Mar. 12, 2026 at 5:20pm

Got story updates? Submit your updates here. ›

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic and molecular testing services, saw its stock price drop 7.9% during mid-day trading on Thursday. The stock traded as low as $8.10 and closed at $7.87, with 177,453 shares changing hands, a decline of 91% from the average session volume.

Why it matters

The significant drop in NeoGenomics' stock price has raised questions among investors about whether they should sell their shares. The company's performance and future outlook will be closely watched by the market as it navigates the competitive landscape of the cancer diagnostics industry.

The details

Several Wall Street analysts have weighed in on NeoGenomics' stock. TD Cowen reiterated a "buy" rating on the shares, while Weiss Ratings downgraded the stock to a "sell (d-)" rating. Benchmark and UBS Group both maintained "hold" ratings on the stock. Overall, the consensus rating from analysts is "Hold" with a price target of $11.86.

  • NeoGenomics' stock price dropped 7.9% during mid-day trading on Thursday, March 12, 2026.

The players

NeoGenomics, Inc.

A leading provider of cancer-focused genetic and molecular testing services, headquartered in Fort Myers, Florida.

TD Cowen

A Wall Street research firm that reiterated a "buy" rating on NeoGenomics' stock.

Weiss Ratings

A Wall Street research firm that downgraded NeoGenomics' stock to a "sell (d-)" rating.

Benchmark

A Wall Street research firm that maintained a "hold" rating on NeoGenomics' stock.

UBS Group

A Wall Street research firm that maintained a "hold" rating on NeoGenomics' stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The drop in NeoGenomics' stock price highlights the volatility and uncertainty in the cancer diagnostics industry, and investors will be closely watching the company's performance and strategic moves in the coming months to determine if the stock remains a worthwhile investment.